Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TLSaRNA

Financiado

Artificial induction of tertiary lymphoid structures (TLS) in tumors using intra...

Artificial induction of tertiary lymphoid structures (TLS) in tumors using intratumoral mRNAs to evaluate its synergy with immune checkpoint inhibitors Tertiary lymphoid structures (TLS) are ectopically generated lymphoid structures with some level of cellular organisation similar to the secondary lymphoid organs, characterised by having a B-cell zone adjacent to a T-cell zone. T... ver más

31/03/2026

FUNOACION PARA LA...

181K€

Presupuesto del proyecto: 181K€

Líder del proyecto

FUNOACION PARA LA INVESTIG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 12M€

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-01

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

FUNOACION PARA LA INVESTIG

181.15K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

FOLOME Role of tissue-resident FOLR2+ Macrophages as Organizers of... 2M€ Cerrado

SAF2017-83732-R REPROGRAMACION DEL MICROAMBIENTE TUMORAL PARA AUMENTAR LA EF... 339K€ Cerrado

SAF2014-54475-R MIGRACION, ACTIVACION Y DISFUNCION DE LINFOCITOS T EN CANCER 399K€ Cerrado

MOTM Metabolic optimisation of intra-tumoral T cell motility 212K€ Cerrado

SMART-NHL Studying the Microenvironment And Related Targets in Non-Hod... 181K€ Cerrado

MiTE Developing the next generation of cis-targeting macrophage-T... 150K€ Cerrado

Duración del proyecto: 24 meses Fecha Inicio: 2024-03-01
Fecha Fin: 2026-03-31

Líder del proyecto

FUNOACION PARA LA INVESTIG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 12M€

Presupuesto del proyecto 181K€

Descripción del proyecto Tertiary lymphoid structures (TLS) are ectopically generated lymphoid structures with some level of cellular organisation similar to the secondary lymphoid organs, characterised by having a B-cell zone adjacent to a T-cell zone. The presence of tumor immune infiltrates, especially in the form of TLS, has been linked to a better cancer prognosis in different types of tumor and improved response to immune checkpoint inhibitors (ICB). However, interestingly, not all the patients develop TLS and the cellular composition and organisation within the structures can vary. Specifically, the role of B cells in the tumor microenvironment is controversial, while some studies have reported a pro-tumoral effect, possibly through differentiation of regulatory B cells, metadata shows a strong association between the presence of a transcriptional B cell profile on the tumors and the improved patient outcome. Moreover, the presence of B cells in the tissue microenvironment is also positively associated with an improved response to ICB. However, even though these strong statistical associations and the relevance of TLS in the cancer prognosis, still little is known about the mechanisms underlying their function and the specific role of B cells in the anti-tumoral response elicited. In this proposal, we will study novel therapies for artificial TLS induction by using intratumoral injection of mRNAs encoding for specific cytokines. We will deeply characterise the synergy between immunotherapy treatments and TLS in the tumor development by using the state-of-the art spatial transcriptomics and immunophenotyping. Finally, we will decipher the function of tumor-specific B cells on the tumor microenvironment and the relevance of tumor-specific secreted antibodies in the overall anti-tumoral response. Ultimately, the knowledge generated with this proposal will provide relevant information to guide future immunotherapy treatments.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores